Trials / Unknown
UnknownNCT01282658
Pharmacogenomics Study of CPT-11 as the First-line Chemotherapy for mCRC
Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Huazhong University of Science and Technology · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Irinotecan (CPT-11) is now widely used as the first-line chemotherapy for mCRC. There were 4 key enzymes for CPT-11 metabolizing, CYP3A4, UDP-glucuronosyltransferase, carboxylesterase(CES), and ATP-binding cassette (ABC) transporters. Genetic variations of those enzymes may cause the heterogeneity in safety and efficacy of CPT-11. The aim of this study is to figure out the correlation between the genetic polymorphism and the drug response.
Detailed description
collect blood samples,determining genetic contribution to the safety and efficacy of CPT-11.
Conditions
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2012-12-01
- Completion
- 2013-05-01
- First posted
- 2011-01-25
- Last updated
- 2011-02-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01282658. Inclusion in this directory is not an endorsement.